Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.

doi:10.1158/1078-0432.CCR-21-3581

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 13 Jun 2022

Philip Philip A, Azar Ibrahim, Xiu Joanne, Hall Michael J, Hendifar Andrew Eugene, Lou Emil, Hwang Jimmy J, Gong Jun, Feldman Rebecca, Ellis Michelle, Stafford Phil, Spetzler David, Khushman Moh'd M, Sohal Davendra, Lockhart A Craig, Weinberg Benjamin A, El-Deiry Wafik S, Marshall John, Shields Anthony F, Korn W Michael

Abstract excerpt

PURPOSE: KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to characterize the molecular profiles of KRAS WT PDAC to uncover new pathogenic drivers and offer targeted treatments. EXPERIMENTAL DESIGN: Tumor tissue obtained from surgical or biopsy material was subjected to next-generation DNA/RNA sequencing,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to DNA Helicases

Share to Microsatellite Instability

Share to Nuclear Proteins

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 35302596
DOI: 10.1158/1078-0432.CCR-21-3581
PMCID: PMC9541577

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.PMID 35302596Read ↗

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinomaSemantic proximity Read ↗

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.Semantic proximity Read ↗

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

Precision medicine for KRAS wild-type pancreatic adenocarcinomas.Semantic proximity Read ↗

Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genesSemantic proximity Read ↗

Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild‐Type Pancreatic CancerSemantic proximity Read ↗

Genomic mutation and Clinicopathological features of KRAS wild-type tumors in Chinese cohort with pancreatic adenocarcinoma.Semantic proximity Read ↗

Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

NRG1 Fusions in KRAS Wild-Type Pancreatic CancerSemantic proximity Read ↗

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersSemantic proximity Read ↗

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.